Dr. Bharathi Pulla, M.D
Adolescent Medicine (Adolescent Medicine (Family Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 14
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Adolescent Medicine (Family Medicine) Physician primary
WI license 41182 -
Geriatric Medicine (Family Medicine) Physician
WI license 41182
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Aurora Medical Center Kenosha Kenosha, WI
- Froedtert South Inc. Kenosha, WI
Medical groups
- Advantage Physical Therapy and Sports Rehab, LLC (294 clinicians)
- Kenosha Community Health Center, Inc. (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 14
- Services billed
- 18
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 234 | 106 |
| Established patient office or other outpatient visit, 20-29 minutes | 123 | 60 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 67 | 67 |
| Annual depression screening, 5 to 15 minutes | 61 | 61 |
| Transitional care management services for problem of high complexity | 28 | 26 |
| Insertion of needle into vein for collection of blood sample | 18 | 18 |
| Hospital discharge day management, more than 30 minutes | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 57 payments worth $1,321 in total to this clinician.
| Novo Nordisk Inc | $325 |
|---|---|
| Ani Pharmaceuticals, Inc. | $174 |
| Abbott Laboratories | $113 |
| Lundbeck LLC | $79.56 |
| AbbVie Inc. | $77.16 |
| Teva Pharmaceuticals USA, Inc. | $63.38 |
| Neurocrine Biosciences, Inc. | $60.23 |
| Exact Sciences Corporation | $59.27 |
| Food and Beverage | $1,321 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $178,856 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
Pfizer Inc. - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.